p27Kip1 is expressed in proliferating cells in its form phosphorylated on threonine 187
© Troncone et al; licensee BioMed Central Ltd. 2005
Received: 18 October 2004
Accepted: 23 February 2005
Published: 23 February 2005
G1/S cell cycle progression requires p27Kip1 (p27) proteolysis, which is triggered by its phosphorylation on threonine (Thr) 187. Since its levels are abundant in quiescent and scarce in cycling cells, p27 is an approved marker for quiescent cells, extensively used in histopathology and cancer research.
However here we showed that by using a specific phosphorylation site (pThr187) antibody, p27 is detectable also in proliferative compartments of normal, dysplastic and neoplastic tissues.
In fact, whereas un-phosphorylated p27 and MIB-1 showed a significant inverse correlation (Spearman R = -0.55; p < 0,001), pThr187-p27 was positively and significantly correlated with MIB-1 expression (Spearman R = 0.88; p < 0,001). Thus proliferating cells only stain for pThr187-p27, whereas they are un-reactive with the regular p27 antibodies. However increasing the sensitivity of the immunocytochemistry (ICH) by the use of an ultra sensitive detection system based on tiramide signal amplification, simultaneous expression and colocalisation of both forms of p27 was shown in proliferating compartments nuclei by double immunofluorescence and laser scanning confocal microscopy studies.
Overall, our data suggest that p27 expression also occurs in proliferating cells compartments and the combined use of both regular and phospho- p27 antibodies is suggested.
Immunocytochemistry (ICH) is an important method for identification of proteins in cells and in tissues. Since the biological activity of many proteins is dependent on their phosphorylation status, a challenge for immunocytochemistry is to characterize the protein form and not just the total amount . p27Kip1 (p27) is a key inhibitor of cell division that protects tissues from excessive cell proliferation . As a consequence of an altered balance between synthesis and degradation, the amounts of this protein are abnormally low in advanced and poorly differentiated neoplasms . Since p27 expression is readily assessed by ICH, this protein is a prognostic marker quite popular in histopathology . However, little is known on its in vivo regulation. p27 cellular levels, copious in quiescent cells undergoing terminal differentiation, are scanty in cycling cells ; in these cells p27 is phosphorylated on Thr 187 by cyclin-dependent kinase (cdk) 2 in late G1 . This event leads to enhanced ubiquitination and p27 proteolysis by the proteasome, which marks the restriction point and promotes cell proliferation .
Therefore un-phosphorylated ("plain") p27 is representative of the total protein amounts only in quiescent cells, whereas in cycling cells a fraction of p27 is transiently present in the pThr187 form before degradation . Recently, Montagnoli et al raised an antibody (Ab), specific for pThr187-p27 that was reactive in immunoprecipitates from proliferating cells and negative in quiescent cells . Even more recently this Ab was shown to be reactive also on paraffin sections [7, 8]. The present study was undertaken to assess pThr187-p27 Ab staining pattern in a wide range of normal, dysplastic and neoplastic tissues; its expression was correlated to those of MIB-1, a standard marker of proliferation, and of "plain" p27. The relationship between the two forms of p27 was also studied at a sub cellular level by double immunofluorescence (IF) and laser scanning confocal microscopy (LSCM). Here we show that p27 expression is not restricted to quiescent cells but that it also occurs in proliferating cellular compartments, where it is detectable by regular ICH only in its pThr187 form. Therefore, to fully assess p27 tissue expression both antibodies should be used.
pThr187-p27 was detected by the 71–7100 polyclonal antibody (PcAb) (Zymed Laboratories, San Francisco, CA, USA) and by the sc-16324 PcAb (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). These Ab's were raised against a short peptide corresponding to the portion of human p27 containing phosphorylated Thr-187, in order to detect only phospho-p27 and to be unreactive with "plain"-p27. The 71–7100 Ab was previously employed in immuno-precipitation experiments by Western blot, [6, 9, 10] and to immunostain neoplastic and degenerative human tissue [7, 8].
"Plain" p27 protein levels were detected with the K10125 monoclonal Ab (McAb) from (Transduction Laboratories, Lexington, Ky, USA), and with the rabbit PcAb (C-19) (Santa Cruz Biotechnology). These antibodies were previously shown to share the same staining pattern . MIB-1 McAb from Novocastra (Newcastle upon Tyne, UK) was used to stain proliferating cells and as control of antigenic preservation and of successful antigenic retrieval .
pThr187-p27, "plain"-p27 and MIB-1 expression in normal tissues.
Normal squamous epithelium skin, tonsil, larynx, cervix.
Germinal centers Tonsil, lymphnode, apendix
Bowel Crypt cells
Xylene dewaxed and alcohol rehydrated paraffin sections were placed in Coplin jars filled with a 0.01 M tri-sodium citrate solution, and heated for 3 minutes in a conventional pressure cooker . After heating, slides were thoroughly rinsed in cool running water for 5 minutes. They were then washed in Tris-Buffered Saline (TBS) ph 7.4 before incubating overnight with the specific Ab, diluted as follows: anti-pThr187-p27 (Zymeed) 1:1000; anti-pThr187-p27 (Santa Cruz) 1:200; anti-p27 (Transduction) 1:4000; anti-p27 (Santa Cruz) 1:50; anti-Ki-67 1:50. After incubation with the primary Ab, tissue sections were covered with biotinylated anti-mouse or anti-rabbit immunoglobulins, followed by peroxidase labelled streptavidine (LSAB-DAKO); the signal was developed by using diaminobencidine (DAB) chromogen as substrate.
pThr187-p27 antibody specificity was controlled by Western blot analysis of MDA MB 468 (breast cancer) and NPA (thyroid papillary cancer) cell lines. These were lysed (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 0.1% Triton X-100, 5 mmol/L ethylenediaminetetraacetic acid, 1 mmol/L Na3VO4, and 1 mmol/L phenyl methyl sulfonyl fluoride and protease inhibitors) and 20 to 30 μg of proteins were electrophoresed in sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and transferred onto nitrocellulose membranes. The membranes were first blocked and then incubated with the primary antibody as it follows: anti-pThr187-p27 (Zymeed), 1:2000 and anti "plain" p27 (Transduction), 1:3000 for 1 hour at room temperature. To confirm equal loading, membranes were immunoblotted with monoclonal anti b-tubulin antibody (1:1000, Santa Cruz). After three washes, filters were incubated with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies (1:2000; Amersham, Arlington Heights, IL, USA) for 1 hour at room temperature. Detection of immunocomplexes was performed with an enhanced chemiluminescence system (ECL, Amersham).
pThr187-p27 immunostaining specificity was assessed by several control experiments performed in parallel, in which the primary Ab was either replaced by a similarly diluted normal rabbit serum, or adsorbed with increasing concentrations of its phospho and dephosphopeptides (up to 0.14 mg mL-1).
Quantitative study and statistical analysis
Range of positive cells for pThr187-p27, "plain"-p27 and MIB-1 expression in different type of carcinomas
ISCC cervix n = 9
ISCC oral n = 7
ISCC lung n = 10
Thyroid, papillary carcinoma n = 6
Thyroid, anaplastic carcinoma n = 5
Breast carcinoma n = 12
Colonic carcinoma n = 6
Prostate carcinoma n = 5
Glioblastoma n = 5
Chorioncarcinoma n = 2
Double Immunofluorscence (IF) staining and Laser Scanning Confocal Microscopy (LSCM)
Tissue sections from both normal and neoplastic specimens were also stained using double IF labelling for pThr187-p27 and "plain" p27, according to previous studies with minor modifications . The primary anti pThr187-p27 (Zymeed) was incubated (1/1000) for 1 hour, followed by incubation with swine anti rabbit HRP (1/200) (Dako) and Cy3 tyramide amplification (Perkin Elmer Life Sciences). To avoid cross-reactivity due to residual HRP, sections were incubated with 0.3% H2O2 for 1 hour. The primary mouse McAb anti p27 (1/4000) was detected by overnight incubation at 4°C, followed by goat anti mouse HRP (1/200, DAKO). After washing in TBS, sections were incubated with fluorescein isotiocyanate (FITC) tyramide amplification (Perkin Elmer Life Sciences) and mounted with Vectashield-DAPI mounting medium (Vector). Control sections in which the second primary Ab was omitted were included to ascertain destruction of peroxidase activity. Single IF stained sections as well as colorimetric immunostaining were used as controls of signal specificity. Slides were examined with a Leica TCS SP2 UltraSpectral LaserScan Confocal microscope. FITC was excited at 488 and detected with a bandpass 500 to 550 nm. Cy3 was excited at 514 nm and detected with a bandpass 580 to 655 nm. Series of images were processed with the Leica confocal soft package. Confocal images were captured and imported into Adobe Photoshop 7 (Adobe Systems, Mountain View, CA) and processed with an eMac personal computer.
pThr187-p27 expression in normal tissues
In other normal tissues, comprising breast, lung, kidney, pancreas, prostate, thyroid and parathyroid, "plain" p27 was expressed by the vast majority of cells, whereas pospho-p27 single labelled cells could be made out by meticulous scrutiny; in these tissues also MIB-1 staining was sporadic.
pThr187-p27 expression in dysplastic and neoplastic tissues
A wide range of different tumours was examined, in order to assess whether staining for phospho-p27 may yield diagnostic information in addition to those provided by "plain p27" (Table 2). As a general rule, the expression of the two forms of p27 was alternative and dependent on the degree of tumour differentiation, recapitulating the pattern featured by normal and dysplastic tissues; phospho-p27 strongly labelled aggressive tumours, whereas "plain p27" staining was only retained by well differentiated tumours. Thus, poorly differentiated and highly proliferating adenocarcinoma of the breast, colon and prostate were strongly labelled by the pThr187-p27 Ab, (Figure 2C–D) whereas "plain p27" staining was only retained by well differentiated neoplasms. The above staining differences between the two forms of p27 were also evident in squamous cell carcinomas. Poorly differentiated neoplasms, composed of nests of small undifferentiated cells with high MIB-1 index and minimal keratinisation, showed intense staining for pThr187-p27 (Figure 2E) whereas "plain p27" labelled those neoplasms showing abundant keratin, squamous pearl formation and low mitotic activity. Similarly, anaplastic thyroid carcinoma showed pThr187-p27 staining stronger than papillary carcinomas, while in this latter "plain p27" was prevalent (Table 2). An intense pThr187-p27 expression was also found in choriocarcinoma (Figure 2F), in which the level of "plain-p27" staining was instead low. The Spearman's correlation coefficient for continuous variables revealed a positive and a significant correlation between pThr187-p27 staining and MIB-1 expression (Spearman R = 0.88; p < 0,001). On the contrary both pThr187-p27 and "plain" p27 (Spearman R = -0.61; p < 0,001) and MIB1 and "plain" p27 (Spearman R = -0.55; p < 0,001) showed significant inverse correlations.
Double IF & LSCM studies
p27 is an approved marker for quiescent cells, extensively used in histopathology and cancer research. However here we showed that an unusual p27 expression pattern may be obtained when only its portion phosphorylated on threonine 187 is stained. By using a specific phosphorylation site antibody, p27 expression may be detected in the proliferative compartments of squamous and intestinal epithelia, of lymph node germinal centres, of trophoblastic villi, of cervical and colonic pre-invasive lesions and of several carcinomas types. These results are similar to those reported in vitro by Montagnoli et al, who also detected p27 expression in proliferating cells by the pThr187-p27 Ab . The same antibody, here, employed to stain a wide range of normal, dysplastic and neoplastic tissues yielded a pattern similar to that of Ki-67 (Spearman R = 0.88; p < 0,001), underlining the close association between cell proliferation and the expression of that portion of p27 targeted for degradation. Since pThr187-p27 Ab should react with cells from late G1 through G2-M, whereas MIB-1 stains throughout the entire cell cycle, it is also conceivable that the pThr187-p27 Ab stained a lower percentage of cells than MIB-1/Ki-67 in both normal (Table 1) and neoplastic tissue. (Table 2)
In this study we showed that p27 expression does not feature only one pattern, but that two different staining may be obtained by the use of either regular or pThr187 antibodies; in fact, when the overall data relative to the expression of p27 by both antibodies in tumours were analysed, a significant inverse correlation between the two forms was found (Spearman R = -0.61; p < 0,001). This data reflects the different relationship between each form of p27 and tissue differentiation:aggressive tumours were strongly labelled by phospho-p27 Ab, whereas plain-p27 was prevalent in well differentiated tumours. Thus the ratio between the two forms of p27, more than the total protein amounts, could yield information on tumour differentiation and behaviour.
Since cdk2 activity is low in differentiating cells and p27 is only present in its un-phosphorylated form, it is reasonable that squamous superficial layers, upper half of the intestinal crypts, lymphoid mantle cells and syncytiotrophoblastic cells only react with the regular antibodies. More intriguing is the search for the reasons explaining why in proliferating cells p27 is detected by the pThr187-Ab and missed by the regular antibodies. The possibility of an aberrant cross-reactivity by the pThr187-Ab was excluded both by Western blot analysis and by phosphopeptide adsorbtion. Montagnoli et al, who also confirmed antibody specificity by biochemical assays, showed that p27 expression may be better detected by using both antibodies than either alone and that there is a portion of p27 that is only recognizable by the anti-phospho Ab . Thus, in proliferating cells anti-pThr187 Ab may be more efficient than the regular p27 antibodies, being protein levels low and mainly present in their phosphorylated form. To test this hypothesis, the sensitivity of the p27 detection by the regular antibodies was increased by the use of an ultra sensitive detection system based on tiramide signal amplification and observed at high resolution by laser scanning confocal microscopy. The results obtained by this approach were slightly different to those obtained by colorimetric IHC, as p27 was simultaneously detected by both antibodies in the same nuclei of the proliferating compartments; in particular the signal generated by both antibodies showed specific colocalitation by double immunofluorescence.
In this study we have reported the following observations: (1) pThr187-p27 Ab selectively stains proliferating cells; (2) this staining does not identify the "plain" p27 protein, expressed by quiescent cells. Therefore, the pThr187-p27 antibody is a useful tool to study p27 in vivo regulation. Indeed, the pattern of expression observed in this study, strongly suggest that the anti-pThr187-p27 Ab identifies proliferating cells. Considering the importance of the different biological functions of p27: regulator of cell growth, cell differentiation, contact inhibition, apoptosis, protection against immunological aggression, and protection against environmental stress, among others, the combined use of both "plain" and pThr187 p27 antibodies will be a useful tool to better characterize the biology of these conditions.
We are grateful to Ms M A Ollacarizqueta and Ms D Gomez Donaire for their excellent technical assistance with LSCM studies and double IF staining respectively. This study was co-financed by PRIN and by Italia- Spagna Azioni Integrate grants from the Ministry of Università e Ricerca Scientifica (MIUR) and from Regione Camparia
- Mandell JW: Phosphorylation state specific antibodies. Applications in investigative and diagnostic pathology. Am J Pathol. 2003, 163: 1687-1698.PubMed CentralView ArticlePubMed
- Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994, 78: 59-66. 10.1016/0092-8674(94)90572-X.View ArticlePubMed
- Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer B: p27Kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999, 154: 313-23.PubMed CentralView ArticlePubMed
- Steeg PS, Abrams JS: Cancer prognostics: past, present and p27Kip1. Nat Med. 1997, 3: 152-154. 10.1038/nm0297-152.View ArticlePubMed
- Vlach JS, Hennecke S, Amati B: Phosphorylation dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. EMBO J. 1997, 16: 5334-5344. 10.1093/emboj/16.17.5334.PubMed CentralView ArticlePubMed
- Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes & Develop. 1999, 13: 1181-1189.View Article
- Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB: Expression of phosphorylated p27Kip1 protein and Jun activation domain binding protein 1 in human pituitary tumours. J Clin Endocrinol Metabol. 2002, 87: 2635-2643. 10.1210/jc.87.6.2635.View Article
- Ogawa O, Lee HG, Zhu X, Raina A, Harris PL, Castellani RJ, Perry G, Smith MA: Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell. 2003, 2: 105-110. 10.1046/j.1474-9728.2003.00042.x.View ArticlePubMed
- Liu W, Asa SL, Fantus IG, Walfish GP, Ezzat S: Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation trough PTEN/AKT dependent and independent pathway. Am J Pathol. 2002, 160: 511-519.PubMed CentralView ArticlePubMed
- Liu W, Asa SL, Ezzat S: Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. Brain Pathol. 2002, 12: 412-429.View ArticlePubMed
- Sanchez-Beato M, Saez AI, Martinez-Montero JC, Sol Mateo M, Sanchez-Verde L, Villuendas R, Troncone G, Piris MA: Cyclin-Dependent Kinase Inhibitor p27Kip1 in Lymphoid Tissue. P27 Expression is inversely proportional to the proliferative index. Am J Pathol. 1997, 151: 151-160.PubMed CentralPubMed
- Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigens (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992, 168: 357-363.View ArticlePubMed
- Jordan RCK, Bradley G, Slingerland J: Reduced levels of cell-cycle inhibitor p27 in epitelial dysplasia and carcinoma of oral cavity. Am J Pathol. 1998, 152: 585-589.PubMed CentralPubMed
- Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, Mikata A, Harigaya K, Kuriyama T: Role of p27 and cyclin-dependent kinase 2 in the proliferation of non small cell lung cancer. Am J Pathol. 1998, 153: 505-513.PubMed CentralView ArticlePubMed
- Troncone G, Vetrani A, de Rosa G, Gerbasio D, Palombini L: Cyclin-dependent kinase inhibitor p27Kip1 in normal and neoplastic cervical epithelium. J Clin Pathol. 1999, 52: 880-887.PubMed CentralView ArticlePubMed
- Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell cycle regulators p27/kip1 and cyclin E, alone and in combination, correlate with survival in young breast. Nat Med. 1997, 3: 222-5. 10.1038/nm0297-222.View ArticlePubMed
- Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1 in aggressive colorectal carcinomas. Nature Med. 1997, 3: 231-234. 10.1038/nm0297-231.View ArticlePubMed
- Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, Thompson TC, Wheeler TM: Levels of expression of p27Kip1 protein in humane prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol. 1999, 12: 751-755.PubMed
- Tallini G, Garcia-Rostan G, Herrero A, Tallini G, Garcia-Rostan G, Herrero AL: Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol. 1999, 23: 678-85. 10.1097/00000478-199906000-00007.View ArticlePubMed
- Kirla RM, Haapasalo HK, Kalimo H, Kirla RM, Haapasalo HK, Kalimo H, Salminen EK: Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer. 2003, 97: 644-8. 10.1002/cncr.11079.View ArticlePubMed
- Olvera M, Harris S, Amezcua CA, McCourty A, Rezk S, Koo C, Felix JC, Brynes RK: Cdk-2, Cyclin E, p27(kip1), and Ki-67 in normal placenta and gestational trophoblastic disease. Mod Pathol. 2001, 14: 1036-42. 10.1038/modpathol.3880432.View ArticlePubMed
- Sánchez-Beato M, Camacho FI, Martínez-Montero JC, Sáez AI, Villuendas R, Sánchez-Verde L, García JF, Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 over-expression. p27/KIP1- cyclin D3 colocalization in tumor cells. Blood. 1999, 94: 765-772.PubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6890/5/3/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.